Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jul:205:87-92.
doi: 10.1016/j.autneu.2017.03.001. Epub 2017 Mar 10.

Sudomotor dysfunction as a measure of small fiber neuropathy in type 1 diabetes

Affiliations
Clinical Trial

Sudomotor dysfunction as a measure of small fiber neuropathy in type 1 diabetes

Lynn Ang et al. Auton Neurosci. 2017 Jul.

Abstract

Background: This study evaluated whether measuring the electrochemical skin conductance (ESC), as an indirect measure of sudomotor function, may be also a reliable surrogate for early cardiovascular autonomic neuropathy (CAN).

Methods: Longitudinal study included 37 type 1 diabetes (T1D) subjects (mean age 38±13years, duration 15±7years, HbA1c 7.9±1.1%, no known complications at baseline), and 40 age-matched healthy control (HC) subjects. Mean hands ESC (ESChands) and feet (ESCfeet) were measured with the SUDOSCAN (Impeto Medical, France). CAN was assessed with heart rate variability (HRV) studies (ANSAR Inc., PA), cardiovascular autonomic reflex tests (deep-breathing, Valsalva, postural test), and positron emission tomography with sympathetic analogue [11C]meta-hydroxyephedrine. Associations between measures of CAN and ESC were estimated using Spearman correlations. Longitudinal changes were analyzed using paired t-test.

Results: At baseline, there were no differences between T1D and HC in ESChands (69±14 vs. 69±13μS; P=0.84) or ESCfeet (82±8 vs. 78±9μS; P=0.12), while some indices of HRV and Valsalva ratio were significantly lower in T1D vs. HC. T1D subjects experienced a significant decline in both ESChands and ESCfeet at 12months (mean change -7.2±11.6µS, P=0.0006; -2.8±7.3µS, P=0.023 respectively). No significant correlations were consistently found between ESC and measures of CAN at baseline or at 12months.

Conclusion: Comparing patients with T1D to controls, no differences in ESC were observed at baseline. The associations between ESC and established measures of CAN were inconsistent, which does not support ESC as a reliable surrogate for CAN. While both hands and feet ESC declined over time, the significance of this finding is unclear and warrants further reliability testing.

Keywords: Cardiovascular autonomic neuropathy; Diabetic neuropathy; Sudomotor function; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Author Disclosure Statement: No other competing financial interests exist

References

    1. International Diabetes Federation. IDF Diabetes Atlas. 7. Brussels, Belgium: International Diabetes Federation; 2015. http://www.diabetesatlas.org/
    1. Eastman R. National Diabetes Information, Clearinghouse. 2. 1995. Neuropathy in Diabetes; pp. 339–360.
    1. Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Transl Res. 2012;5:463–478. - PMC - PubMed
    1. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. - PMC - PubMed
    1. Callaghan B, Little A, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543. - PMC - PubMed

Publication types